Girard Partners LTD. lifted its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 3.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,249 shares of the medical research company’s stock after acquiring an additional 609 shares during the period. Girard Partners LTD.’s holdings in Thermo Fisher Scientific were worth $3,358,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Sharkey Howes & Javer grew its position in Thermo Fisher Scientific by 1.0% in the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the period. Beacon Trust Co. grew its position in Thermo Fisher Scientific by 0.6% in the 1st quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after purchasing an additional 12 shares during the period. Dumont & Blake Investment Advisors LLC grew its position in Thermo Fisher Scientific by 0.3% in the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after purchasing an additional 15 shares during the period. Reinhart Partners Inc. grew its position in Thermo Fisher Scientific by 0.6% in the 2nd quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock worth $598,000 after purchasing an additional 20 shares during the period. Finally, Azimuth Capital Management LLC grew its position in Thermo Fisher Scientific by 0.8% in the 1st quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock worth $493,000 after purchasing an additional 25 shares during the period. 83.36% of the stock is owned by institutional investors.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at 193.43 on Friday. The stock has a market cap of $75.46 billion, a PE ratio of 33.70 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The stock’s 50 day moving average is $186.10 and its 200 day moving average is $173.62.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.03 earnings per share. Analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

A number of equities research analysts have commented on the stock. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Cowen and Company reaffirmed an “outperform” rating and issued a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Barclays PLC reaffirmed an “overweight” rating and issued a $215.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and a consensus price target of $202.21.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/06/girard-partners-ltd-has-3-36-million-position-in-thermo-fisher-scientific-inc-tmo.html.

In related news, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the sale, the senior vice president now directly owns 67,016 shares of the company’s stock, valued at $11,796,156.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jim P. Manzi sold 11,318 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares in the company, valued at $6,702,635.58. The disclosure for this sale can be found here. Insiders sold 52,738 shares of company stock worth $9,302,112 in the last quarter. Company insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.